Cantex Pharmaceuticals is a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment.

Our lead product candidate, CX-01, is in clinical development for acute myeloid leukemia and lung cancer, and is designed to increase the chances of having a durable complete response to treatment, while, at the same time, reduce serious treatment related side effects.

Latest News


Cantex is advancing its lead product, CX-01, into randomized phase 2 studies in acute myeloid leukemia and small cell lung cancer. These trials are expected to begin in 2015. Clinical and regulatory milestones are expected in 2015, 2016 and 2017.